Life Science Company
Assertio Therapeutics has acquired 2 companies, including 1 in the last 5 years. It has also divested 3 assets.
Assertio Therapeutics’ largest acquisition to date was in 2013, when it acquired Nautilus Neurosciences - CAMBIA® for $49M. It’s largest disclosed sale occurred in 2020, when it sold Assertio Therapeutics - NUCYNTA to Collegium Pharmaceutical for $375M. Assertio Therapeutics has acquired in 2 different US states. The Company’s most targeted sectors include life science (50%) and medical products (50%).
Join Mergr and gain access to Assertio Therapeutics’ M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.
M&A Summary
-
M&A Total Activity5
- M&A Buy Activity2
- M&A Sell Activity3
- Total Sectors Invested 2
- Total Countries Invested 1
- M&A Buy/Sell Connections 4
- M&A Advisors 3
Unlimited Searches
